Immune Response Profiling
Characterize immune dysfunction with the HTG EdgeSeq Immune Response Panel for targeted, high-throughput gene expression profiling
immune system dysfunction in
immune response disease
The HTG EdgeSeq Immune Response Panel leverages the sensitivity and dynamic range of next-generation sequencing (NGS) to measure expression levels of 2,002 genes implicated in a variety of autoimmune diseases.
This panel was designed to provide critical insight into the following applications:
- Evaluate pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and abnormal immune response
- Elucidate therapeutic mechanism of action or validate drug targets
- Measure immunotherapy induced responses
- Discover and validate disease- and therapeutic- specific biomarkers
- Develop predictive signatures of drug response
Therapeutic Categories
- Type I interferon
- Type II interferon
- Innate and adaptive immune-related interleukins
- Tumor necrosis factor (TNF)
- Toll-like receptors
- Immune cell signaling
- Immune checkpoint and co-stimulatory targets
- Other immunomodulatory agents
Disease-Specific Profiling
- Rheumatoid arthritis
- Type 1 diabetes
- Systemic lupus erythematosus
- Ankylosing spondylitis
- Crohn’s disease
- Ulcerative colitis
- Irritable bowel syndrome
- Multiple sclerosis
- Psoriasis
Assay Validation Report
- Lorem ipsum dolor sit amet, consectetur adipiscing elit.
- Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Autoimmune Profiling Supports The Drug Development Lifecycle
The HTG EdgeSeq Autoimmune Panel can be used to evaluate pathways, processes, and cell types involved in autoimmune disease, chronic inflammatory disease, and abnormal immune response.
Biomarker discovery
Discovery & validation of disease and therapeutic- specific biomarkers
Drug development
Target validation and therapeutic mechanism of action studies
Clinical trial monitoring
Immunotherapy induced response event investigations
CDx development
Investigation of predictive signatures of drug response & IVD assay development
See Autoimmune Gene Expression Profiling In Action. Download The Case Studies
Translational Applications In Autoimmune (AI)
And Immuno-oncology (IO)
Mechanism of Action
- Biomarkers could help discover the MOA in patients with adverse responses to AI or IO therapy
- Unique biomarker signatures in patients that do not respond to treatments could be further investigated to identify new drug targets
